A new UCLA imaging study has found that placebo alters brain function in individuals with major depression, showing increased activity in the prefrontal cortex for those who responded to treatment. This discovery challenges traditional views on treatment effectiveness and may lead to the development of new medications.
Researchers have identified matrix metalloproteinases as a key player in the spread of prostate cancer to the bone, offering a new target for treatment. Additionally, a genetic marker may be useful in predicting survival rates for patients with diffuse large B-cell lymphoma, while oral contraceptive use has been found to reduce ovarian...
A new study analyzing oral contraceptive use among women with epithelial ovarian cancer found a significant association between progestin levels and reduced risk. Women using low-progestin/high-estrogen contraceptives were more likely to develop ovarian cancer compared to those using high-progestin/high-estrogen contraceptives.
A study led by Joellen Schildkraut at Duke University Medical Center found that oral contraceptives with higher levels of progestin may be more protective against ovarian cancer than those with lower progestin potency. Higher progestin levels were associated with a significant reduction in risk, even for short periods of use.
A follow-up study of 763 long-term breast cancer survivors found they maintain high levels of health, physical functioning, and emotional well-being. Social support was a significant predictor of current quality of life.